1. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009 Feb;32(2):150–63.
2. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in guillain-barré syndrome. Ann Neurol. 2002 Jun 1;51(6):673–80.
3. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2011 Jan 18;76(3):294–300.
4. Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for guillain-barré syndrome. Ann Indian Acad Neurol. 2011 Jul 1;14(Suppl 1):S73–81.
5. Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;2014(9):CD002063.